NCT03566134 is a Phase 2 clinical trial of DA-8010 2.5mg in Overactive Bladder, sponsored by Dong-A ST Co., Ltd..

Who is sponsoring NCT03566134?

NCT03566134 is sponsored by Dong-A ST Co., Ltd..

What drugs are being tested in NCT03566134?

Interventions in NCT03566134: DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo.

What condition does NCT03566134 study?

NCT03566134 studies Overactive Bladder.

Is NCT03566134 still recruiting?

NCT03566134 is currently completed. Last updated 7 February 2020.

Last reviewed 2020-02-07 · How we verify

NCT03566134

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder

Completed Phase 2 Last updated 7 February 2020

What this trial tests

Phase 2 trial testing DA-8010 Placebo in Overactive Bladder in 306 participants. Completed in 27 December 2019.

Timeline

10 July 2018

Primary endpoint
27 December 2019

27 December 2019

Quick facts

Lead sponsor	Dong-A ST Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	306
Start date	10 July 2018
Primary completion	27 December 2019
Estimated completion	27 December 2019
Sites	1 location across South Korea

Drugs / interventions tested

DA-8010 Placebo — full drug profile →
DA-8010 2.5mg — full drug profile →
DA-8010 5mg — full drug profile →
Solifenacin 5mg — full drug profile →
Solifenacin succinate placebo

Conditions studied

Overactive Bladder — all drugs for Overactive Bladder →

Sponsor

Dong-A ST Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Overactive Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Therapeutic Exploratory Clinical Study to evaluate the efficacy and safety of DA-8010 in Patients with Overactive Bladder and to determine the optimal dose of DA-8010

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults.
Stoniute A, Madhuvrata P, Still M, Barron-Millar E, et al · · 2023 · cited 12× · PMID 37160401 · DOI 10.1002/14651858.cd003781.pub3
Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study.
Son HS, Oh CY, Choo MS, Kim HG, et al · · 2022 · cited 7× · PMID 35793990 · DOI 10.5213/inj.2142382.191
Mixed urinary incontinence: Are there effective treatments?
Game X, Dmochowski R, Robinson D. · · 2023 · cited 4× · PMID 36762411 · DOI 10.1002/nau.25065

Verify or expand the search:

Other trials of DA-8010 2.5mg

Trials testing the same drug.

NCT05282069 — A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder · Phase 3 · completed

Other recruiting trials for Overactive Bladder

Currently open trials in the same condition.

NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
NCT05895045 — Yoga for Treatment of Overactive Bladder in Pediatric Patients · NA · recruiting
NCT07209397 — Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women · NA · recruiting
NCT06921746 — Changes in the Urinary Microbiome and Metabolome During Treatment of the Overactive Bladder in Female Patients · recruiting
NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting

Other Dong-A ST Co., Ltd. trials

Trials by the same sponsor.

NCT07342062 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fed State · Phase 1 · completed
NCT07297940 — Pharmacokinetics and Safety Profiles of DA-1229_01 in Healthy Subjects at Fasting State · Phase 1 · completed
NCT07027982 — A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjec · Phase 1 · completed
NCT07046715 — Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 · Phase 1 · completed
NCT07007533 — A Study to Compare and Evaluate the Safety, Tolerability and Pharmacokinetics Between DA-5223 and DA-5223-R in Healthy A · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03566134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dong-A ST Co., Ltd.
Last refreshed: 7 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03566134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing